Combined analysis of the decays τ−→KSπ−ντ\tau^{-}\to K_{S}\pi^{-}\nu_{\tau} and τ−→K−ηντ\tau^{-}\to K^{-}\eta\nu_{\tau}

The potential of performing a combined analysis of the strangeness-changing decays $\tau^{-}\to K_{S}\pi^{-}\nu_{\tau}$ and $\tau^{-}\to K^{-}\eta\nu_{\tau}$ for unveiling the $K^{*}(1410)$ resonance pole parameters is illustrated. Our study is carried out within the framework of Chiral Perturbation Theory, including resonances as explicit degrees of freedom. Resummation of final state interactions are considered through a dispersive parameterization of the required form factors. A considerable improvement in the determination of the pole position with mass $M_{K^{*}(1410)}=1304\pm17$ MeV and width $\Gamma_{K^{*}(1410)}=171\pm62$ MeV is obtained.Comment: Talk given at XIth Quark Confinement and Hadron Spectrum, 8-12th September (2014), Saint Petersburg (Russia

Jet energy loss in the quark-gluon plasma by stream instabilities

We study the evolution of the plasma instabilities induced by two jets of particles propagating in opposite directions and crossing a thermally equilibrated non-Abelian plasma. In order to simplify the analysis we assume that the two jets of partons can be described with uniform distribution functions in coordinate space and by Gaussian distribution functions in momentum space. We find that while crossing the quark-gluon plasma, the jets of particles excite unstable chromomagnetic and chromoelectric modes. These fields interact with the particles (or hard modes) of the plasma inducing the production of currents; thus, the energy lost by the jets is absorbed by both the gauge fields and the hard modes of the plasma. We compare the outcome of the numerical simulations with the analytical calculation performed assuming that the jets of particles can be described by a tsunami-like distribution function. We find qualitative and semi-quantitative agreement between the results obtained with the two methods.Comment: 10 pages, 3 figure

A Pharmacovigilance Study in First Episode of Psychosis : Psychopharmacological Interventions and Safety Profiles in the PEPs Project

The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice. Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period. The majority of first episode of psychosis patients received a second-generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P=.043). A total of 5.2% of the patients were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received benzodiazepines; and 35.52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85.2% vs 45.5%, P<.001). These data indicate that the overall pharmacologic prescription for treating a first episode of psychosis in Spain follows the clinical practice guideline recommendations, and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, long-acting injectable antipsychotics, antipsychotic combination, and the use of benzodiazepines

Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients

A better understanding of schizophrenia subtypes is necessary to stratify the patients according to clinical attributes. To explore the genomic architecture of schizophrenia symptomatology, we analyzed blood co-expression modules and their association with clinical data from patients in remission after a first episode of schizophrenia. In total, 91 participants of the 2EPS project were included. Gene expression was assessed using the Clariom S Human Array. Weighted-gene co-expression network analysis (WGCNA) was applied to identify modules of co-expressed genes and to test its correlation with global functioning, clinical symptomatology, and premorbid adjustment. Among the 25 modules identified, six modules were significantly correlated with clinical data. These modules could be clustered in two groups according to their correlation with clinical data. Hub genes in each group showing overlap with risk genes for schizophrenia were enriched in biological processes related to metabolic processes, regulation of gene expression, cellular localization and protein transport, immune processes, and neurotrophin pathways. Our results indicate that modules with significant associations with clinical data showed overlap with gene sets previously identified in differential gene-expression analysis in brain, indicating that peripheral tissues could reveal pathogenic mechanisms. Hub genes involved in these modules revealed multiple signaling pathways previously related to schizophrenia, which may represent the complex interplay in the pathological mechanisms behind the disease. These genes could represent potential targets for the development of peripheral biomarkers underlying illness traits in clinical remission stages after a first episode of schizophrenia

Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea.

Non-invasive ventilation (NIV) is an effective form of treatment in patients with obesity hypoventilation syndrome (OHS) who have concomitant severe obstructive sleep apnoea (OSA). However, there is a paucity of evidence on the efficacy of NIV in patients with OHS without severe OSA. We performed a multicentre randomised clinical trial to determine the comparative efficacy of NIV versus lifestyle modification (control group) using daytime arterial carbon dioxide tension (PaCO2) as the main outcome measure. Between May 2009 and December 2014 we sequentially screened patients with OHS without severe OSA. Participants were randomised to NIV versus lifestyle modification and were followed for 2 months. Arterial blood gas parameters, clinical symptoms, health-related quality of life assessments, polysomnography, spirometry, 6-min walk distance test, blood pressure measurements and healthcare resource utilisation were evaluated. Statistical analysis was performed using intention-to-treat analysis. A total of 365 patients were screened of whom 58 were excluded. Severe OSA was present in 221 and the remaining 86 patients without severe OSA were randomised. NIV led to a significantly larger improvement in PaCO2 of -6 (95% CI -7.7 to -4.2) mm Hg versus -2.8 (95% CI -4.3 to -1.3) mm Hg, (p NIV is more effective than lifestyle modification in improving daytime PaCO2, sleepiness and polysomnographic parameters. Long-term prospective studies are necessary to determine whether NIV reduces healthcare resource utilisation, cardiovascular events and mortality. NCT01405976; results